Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
Part of paid clinical trials in Stanford, California.
- Sponsor
- Stanford University
- Study ID
- NCT01678092
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 4 Years - 25 Years
- Healthy Volunteers
- Not accepted
Interventions
- omalizumab — BIOLOGICAL
Study Details
A phase 1 single center study in which omalizumab is dosed normally (according to the product insert) in subjects with atopic dermatitis.
Key Dates
- Start date
- May 31, 2004
- Status verified
- Nov 2015
- Primary completion
- Dec 31, 2006
- Completion
- Dec 31, 2006
Study Design
- Enrollment
- 8 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94022 | - |
Find similar trials in Stanford, CA
By condition
By specialty
By research site
Related Studies
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
- Molecular Signatures of Cutaneous Dupilumab ResponsePHASE4 · Recruiting · University of California, San Francisco · San Francisco, California
- Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECTRecruiting · University of California, San Diego · La Jolla, California
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 · Recruiting · Pfizer · Birmingham, Alabama